First National Trust Co trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 10.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160,944 shares of the company’s stock after selling 17,994 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of First National Trust Co’s investment portfolio, making the stock its 17th largest position. First National Trust Co’s holdings in Johnson & Johnson were worth $25,226,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Pathway Financial Advisors LLC raised its stake in Johnson & Johnson by 4.3% in the 4th quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after purchasing an additional 226 shares during the last quarter. Daiwa Securities Group Inc. grew its position in shares of Johnson & Johnson by 5.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after purchasing an additional 15,490 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co increased its holdings in shares of Johnson & Johnson by 0.6% in the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after purchasing an additional 414 shares during the last quarter. OneAscent Financial Services LLC lifted its position in Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after buying an additional 4,457 shares in the last quarter. Finally, TrueMark Investments LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $1,458,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
JNJ stock opened at $148.95 on Thursday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a market capitalization of $358.47 billion, a P/E ratio of 9.29, a P/E/G ratio of 2.46 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The business’s 50-day moving average is $153.70 and its two-hundred day moving average is $154.97.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the business earned $2.68 EPS. Analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.33%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- CD Calculator: Certificate of Deposit Calculator
- Generac Powers Ahead on the Electrification Mega-Trend
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.